

# Noxopharm Ltd

## Extended survival options

Noxopharm (ASX:BOT) is a clinical stage drug development company with a leading drug candidate in various clinical trials at Phase II level. There is also an active drug development program developing new drug compounds. The company's current lead drug candidate is Veyonda<sup>R</sup> which is an immunotherapy drug designed to boost the effectiveness of all three major forms of cancer treatment - immuno-oncology therapy, radiotherapy and chemotherapy. To that end, the company is engaged in three separate cancer studies – the IONIC-1 Study (Phase I/II) with Bristol Myers Squibb (BMS) to see if Veyonda<sup>R</sup> can overcome resistance to nivolumab (Opdivo<sup>R</sup>) found in most solid cancers; the DAART-2 (Phase II) study to test Veyonda's ability to achieve high rates of abscopal effect in patients with prostate, breast or lung cancers; the LuPIN (Phase I/II) testing ability of Veyonda<sup>R</sup> to boost response to the US\$6b radiopharmaceutical, LuPSMA-617 (Novartis). Veyonda<sup>R</sup> also has unique anti-inflammatory properties, leading to it currently being tested in a Phase 1b trial on COVID-19 where it is being used to block the long term and often fatal outcomes of the virus. The company has also recently established a new subsidiary, Pharmorage, to build on the anti-inflammatory properties of Veyonda<sup>R</sup>.

## Business model

Noxopharm is focussed on seeing Veyonda<sup>R</sup> come to market as a general purpose immunotherapy drug, boosting the anti-cancer response to standard external radiotherapy, intravenous radiotherapy, immuno-oncology drugs and standard chemotherapy drugs. Noxopharm has a stated goal of seeking to partner out Veyonda<sup>R</sup> on the back of Phase II data to a major pharma company and is building an oncology drug pipeline in expectation of Veyonda<sup>R</sup> being the subject of a possible future industry transaction. NOX is already running two clinical trials in combination with major pharma companies – Novartis and BMS. Near term, the company's number 1 priority program is DAART-2 which is entering Phase II and aimed at end-stage prostate cancer. The second phase trial will be implemented by Parexel, a US based clinical research organisation with extensive oncology experience, and involve more than 200 patients on 1 cycle of radiotherapy and 6 cycles of Veyonda<sup>R</sup>. Beyond Veyonda<sup>R</sup>, the company is seeking to add value by exploiting its technology platform to develop non-oncology drugs. It has already spun out one subsidiary, Nyrada Inc (ASX:NYR), with a drug to treat stroke and traumatic brain injuries, and recently established another subsidiary, Pharmorage Pty Ltd, to focus on developing drugs for chronic inflammation and autoimmune diseases.

## Interim result commentary

Noxopharm's cash position as at 4 March 2021 was ~A\$31.7M following receipt of the 2019/20 Federal Government R & D tax rebate on 2 March 2021. The company spent \$3.05m on R&D in H1 FY21 versus \$3.55m in H1 FY20. Costs overall in the half, excluding one-time items (positive fair value movement in a derivative liability) were flat on the prior year.

## Immuno-oncology companies are the closest peers

We look to biotechs focussed on novel immune-oncology treatments for Noxopharm's peers. Some that come to mind in the Australian market include Imugene, Immutep and Telix Pharmaceuticals.

Biotech

12<sup>th</sup> March 2021

### Share details

ASX Code	NOX
Share price	\$0.64
Market Capitalisation	\$177.0M
Shares on issue	278.8M
In the money options (\$0.30-\$0.62 ex price)	54.3M
Cash at 4 March '21	~A\$31.7M
Free float	~87.0%

### Share performance (12 months)



### Upside Case

- Two global pharma companies are involved in Noxopharm trials for Veyonda<sup>R</sup> presenting partnering opportunities
- Significant upside and application should Veyonda<sup>R</sup> prove to be an effective immuno-oncology drug
- Strong cash position (~A\$31.7M at 4 March '21)

### Downside Case

- Mid-stage testing (Phase II)
- Binary outcome
- Long time line to commercial success

### Catalysts/upcoming events

IONIC-1 and DAART-2 start patient recruitment, COVID-19 clinical trial completed

### Comparable companies (Aust/NZ)

Imugene (ASX:IMU), Immutep (ASX:IMM), Telix Pharmaceuticals (ASX:TLX)

### Top 5 shareholders

Graham Kelly	12.78%
Eleanore Goodridge	3.49%
RGT Capital Fund	2.33%
Link Traders	1.77%
RHLC Pty Ltd	1.17%

### Company contacts

Prue Kelly +61 459 022 445  
info@noxopharm.com

### RaaS Advisory contacts

Finola Burke +61 414 354 712  
finola.burke@raasgroup.com

# FINANCIAL SERVICES GUIDE

**RaaS Advisory Pty Ltd**

**ABN 99 614 783 363**

**Corporate Authorised Representative, number 1248415**

**of**

**BR SECURITIES AUSTRALIA PTY LTD**

**ABN 92 168 734 530**

**AFSL 456663**

**Effective Date: 26<sup>th</sup> November 2018**



### About Us

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License ("AFSL") number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR. This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS's services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Level 14, 344 Queen Street, Brisbane, QLD, 4000

RaaS. 20 Halls Road Arcadia, NSW 2159

P: +61 414 354712

E: [finola.burke@raasgroup.com](mailto:finola.burke@raasgroup.com)

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

**What Financial Services are we authorised to provide?** RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
  - Securities
- deal on behalf of retail and wholesale clients in relation to
  - Securities

The distribution of this FSG by RaaS is authorized by BR.

### Our general advice service

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

### Our dealing service

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application form if needed.

### How are we paid?

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

### Associations and Relationships

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS's representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

### Complaints

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR's internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren't satisfied with an outcome, you may contact AFCA, see below. BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: [www.afca.org.au](http://www.afca.org.au); Email: [info@afca.org.au](mailto:info@afca.org.au); Telephone: 1800931678 (free call)

In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

### Professional Indemnity Insurance

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.

#### DISCLAIMERS and DISCLOSURES

This report has been prepared and issued by RaaS Advisory Pty Ltd. This research is issued in Australia by RaaS Advisory and any access to it should be read in conjunction with the Financial Services Guide on the preceding two pages. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. RaaS Advisory provides this financial advice as an honest and reasonable opinion held at a point in time about an investment's risk profile and merit and the information is provided by the RaaS Advisory in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. RaaS Advisory has no obligation to update the opinion unless RaaS Advisory is currently contracted to provide such an updated opinion. RaaS Advisory does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance. RaaS Advisory's principals, employees and associates may hold shares in companies that are covered and, if so, this will be clearly stated on the front page of each report.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise.

The science of climate change is common knowledge and its impacts may damage the global economy. Mitigating climate change may also disrupt the global economy. Investors need to make their own assessments and we disclaim any liability for the impact of either climate change or mitigating strategies on any investment we recommend.

Investors are responsible for their own investment decisions, unless a contract stipulates otherwise. RaaS Advisory does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, RaaS Advisory shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, RaaS Advisory limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable. Copyright 2021 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.